Ethical conduct and values of Daiichi Sankyo
Our corporate governance – acting with the highest standards
Promoting an ethical culture is of prime importance to us. We strive to conduct our business in a way that not only adheres to the applicable laws and regulations of the countries where we operate, but that also takes into account social consciousness and makes a strong social contribution. These ethical standards apply, for our employees as well as for our business partners. Our expectations of ethical and compliant behavior from all employees are articulated in the high standards set out by our Codes of Conduct. We also attach great importance to transparent communication. We establish similarly high standards in our Business Partner Code of Conduct.
We are committed to creating value for all our stakeholders, including shareholders, employees, customers, and the communities in which we operate. Our long-term success is dependent on our ability to uphold the highest compliance and ethical standards, and we believe that doing so is key to building trust and maintaining positive relationships. Therefore, our corporate governance invests in promoting an ethical culture, and continuously improving our compliance programs and processes. By doing so, we aim to not only meet our legal and regulatory obligations, but also to demonstrate our commitment to doing business in a responsible and sustainable manner. By following high ethical standards and conducting business with integrity, we believe we can build a sustainable future for our company and the communities in which we operate.
A number of policies stipulate our expectations (selection):
Transparency
Financial transparency
Daiichi Sankyo is committed to bringing pharmaceutical innovation from bench to bedside. Innovation is paramount in all that we do, from pursuing new medicines and new methods of drug discovery and delivery, to achieving excellence throughout our organization.
Disclosure of payments to healthcare professionals, healthcare organisations and patient organisations
A fruitful working relationship between the pharmaceutical industry and healthcare professionals has helped develop many life-saving medicines and has long been a positive driver for advancements in patient care and the progression of research.
We fully support transparency and are prepared to disclose proper documentation of all our transfers of value to healthcare professionals (HCP), healthcare organisations (HCO) and patient organisations (beneficiaries) under the EFPIA Disclosure Code and according to the Belgian Sunshine Act.
By transfers of value we mean payments such as donations and grants made to healthcare organisations and, in the case of HCPs, fees for services or financial support to attend educational events such as medical congresses.
When published the disclosures include the name of the HCP or HCO, and the total amounts of value received by that individual or organisation in the previous calendar year. This figure is broken down into categories of activity. For HCOs specifically, there are two categories: donations & grants and contribution to costs related to Events (sponsorship agreements). For HCPs and HCOs the categories are contributions to costs related to events such as registration fees, travel and accommodation for attending medical congresses, etc.) and fees for services and consultancy (for example, agreement for delivering clinical trials, speaker fees, consultancy).
We disclose both direct and indirect transfers of value in order to ensure maximum transparency.
Bringing greater transparency to this, already well-regulated, vital relationship between pharmaceutical companies on the one hand and the HCPs and HCOs on the other hand is about strengthening the basis for collaboration in the future. Society has increasingly high expectations for transparency, none more so than in healthcare. We want to ensure we meet those expectations going forward.
Payments made for R&D non-clinical studies, clinical trials and non- interventional studies prospective in nature will also be disclosed in aggregate.
If the beneficiary has a practice or a registered office in Belgium, the documentation and publication of the premiums and benefits must be done in the Belgian Transparency Register of betransparent.be (regardless of where the company is established).
The Belgian Transparency Register can be consulted here
Self-regulated disclosure for Grand Duchy of Luxembourg
In Luxembourg there is no legal obligation to publish premiums and benefits, but Daiichi Sankyo – like all members of the APL – publishes its data on an annual basis. The link to any publication for the GDL can be found here
Click on the year to get the specific Daiichi Sankyo publication:
- Transfers of value Luxemburg 2022
- Transfers of value Luxemburg 2023
- Transfers of value Luxemburg 2024
- Transfers of value Luxemburg 2025
Contact:
If you have any questions regarding transparency at Daiichi Sankyo Belgium, please contact us via legal_be@daiichisankyo.com
